stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Total debt
Krystal Biotech, Inc.'s total debt at the end of fiscal 2022 was $7.4M, up 5.57% from $7.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $8.3M. Over the past ten years it has ranged from $1.8M (fiscal 2016) to $7.4M (fiscal 2022) — the current reading is the highest in ten years. Krystal Biotech, Inc. ranks 253rd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $7.4M | 5.57% |
| FY2021 | $7.0M | 111.09% |
| FY2020 | $3.3M | 18.91% |
| FY2019 | $2.8M | 50.95% |
| FY2016 | $1.8M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $8.3M | (2.61%) |
| Jun 2023 | $8.5M | (2.45%) |
| Mar 2023 | $8.8M | (1.96%) |
| Dec 2022 | $8.9M | (2.07%) |
| 15 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| KRYS Krystal Biotech, Inc. | $8.3M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement